HOME >> MEDICINE >> NEWS
Researchers seek new hope in old asthma treatment

Theophylline (pronounced theeoffaleen), an asthma medication prescribed since the 1950s, is now being studied for new potential merits. The Effectiveness of Low Dose Theophylline as Add-On Therapy in the Treatment of Asthma or LODO trial is sponsored by the 19 American Lung Association (ALA) Asthma Clinical Research Centers (ACRC) across the country and seeks to enroll over 600 people, age 15 and over, who suffer from persistent asthma symptoms despite treatment. The ALA ACRC at the University of Vermont (UVM), headed by Professor of Medicine and Vermont Lung Center Director Charles Irvin, Ph.D., is the lead study site.

An estimated 26 million Americans have been diagnosed with asthma. About a third of all asthma sufferers are unable to manage their asthma well, Irvin said. The LODO study aims to test its effectiveness as an add-on therapy for this population.

Theophylline is a pill-form asthma treatment classified as a bronchodilator that has been used for over 50 years to help open narrow, inflamed airway passages. The medication became associated with side effects and drug interactions and fell out of favor when newer treatment options became available. Recent studies in such scientific journals as The Lancet and the American Journal of Respiratory Critical Care Medicine suggest that theophylline may have the capacity to reduce airway inflammation and clear away mucus in doses one-quarter to one-third of those needed to open asthmatic passages. So scientists decided to give theophylline another chance.

The LODO study seeks to identify whether or not theophylline can be an effective add-on therapy a booster, so to speak that will produce better overall results for asthmatics. The study will compare the effectiveness and side-effects of low doses of theophylline to montelukast (sold as Singulair), as well as placebo (sugar pill), on asthma patients. During the double-blind study, the patient, the doctor and the research staff
'"/>

Contact: Jennifer Nachbur
jennifer.nachbur@uvm.edu
802-656-7875
University of Vermont
10-May-2002


Page: 1 2

Related medicine news :

1. Researchers search for first sign of congestive heart failure
2. Researchers say breast cancer in Africa may provide clues to the disease in African-Americans
3. Researchers close in on breast cancer vaccine
4. Researchers discover link between insulin and Alzheimers
5. Researchers model brains electrical storm during a seizure
6. Researchers track programs success in curbing aggressive behavior
7. Researchers confirm Vioxx nearly doubled cardiovascular risks in cancer prevention study
8. Researchers offer emergency workers a lifeline
9. Researchers discover genetic variant that may explain why women develop M.S. more than men
10. Researchers map the sexual network of an entire high school
11. Researchers hope monkeys can provide new insights into depression

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... today the introduction of an innovative new design of the shoulder pad. The ... get maximum comfort while controlling your pain while using cold therapy. By utilizing ice ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... ... 2017 , ... Leading pediatric oncology experts at Children’s National Health System ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... nation's first interactive health literacy software tool, and the Cancer Patient Education Network ... cancer patient education, today announce a new strategic alliance. , As CPEN’s ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... ... Cal Dining at the University of California Berkeley, and other leading institutions in ... the buying power of institutions to change the way animals are raised for ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global ... that its MyDario product is expected to appear on The Dr. Oz ... Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked ... The segment features ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
(Date:9/22/2017)... Md. , Sept. 22, 2017  As the ... Republican Senators Bill Cassidy (R-LA) and ... Information notes that the medical device industry is in ... medical device tax, the 2.3% excise tax on medical ... But they also want covered patients, increased visits and ...
Breaking Medicine Technology:
Cached News: